Specifically, we characterized a group of beta-catenin interacting proteins whose expression is potentially controlled by beta-catenin; we proposed a mechanism for regulation of beta-catenin transcriptional activity by the cyclin dependent kinase CDK5, which was identified as a beta-catenin regulator in a large-scale miRNA-based knock-down screen of the kinome [8]; and finally, we examined beta-catenin cancer-associated mutations in conjunction with other sequence features to determine how beta-catenin activity may be altered in different cancer types. This evidence concerns the gene CDK5 and cancer.